Key Takeaways
- The Vanguard Health Care ETF (VHT) offers broad sector diversification with a higher dividend yield, while the iShares Biotechnology ETF (IBB) focuses on specialized biotech stocks.
- VHT has a lower expense ratio, making it more cost-effective for long-term investors compared to IBB.
- IBB provides higher risk and potential rewards due to its concentration in biotechnology, which may suit aggressive investors.
Overview of ETFs
The Vanguard Health Care ETF (VHT) and iShares Biotechnology ETF (IBB) represent two different investment strategies in the healthcare sector. VHT provides diversified exposure across various healthcare industries, while IBB focuses solely on biotechnology companies, appealing to investors looking for high-growth opportunities.
Cost and Performance Analysis
As of July 1, 2026, the share prices are $300.84 for VHT and $190.12 for IBB. VHT boasts a lower expense ratio of 0.09% compared to IBB’s 0.44%, making it more advantageous for long-term holders. The one-year returns reflect this trend, with IBB at 49.3% versus VHT’s 21.8%. VHT also gives a higher dividend yield of 1.6% compared to IBB’s 0.2%, appealing to income-focused investors.
When assessing performance risks, VHT demonstrates a lower maximum drawdown over five years (17.7%) compared to IBB’s (39.8%). An investment of $1,000 in VHT would have grown to $1,291 over five years, opposed to $1,170 for IBB.
Portfolio Composition
VHT includes 429 holdings, with major positions in Eli Lilly (14.01%), Johnson & Johnson (8.45%), and AbbVie (6.08%). This diversified strategy mitigates risks related to specific industries within healthcare. Launched in 2004, it has returned $4.72 per share in dividends over the last year.
IBB, in contrast, consists of 248 stocks focusing mainly on biotech firms, with significant holdings in Vertex Pharmaceuticals (8.1%), Amgen (7.81%), and Gilead Sciences (6.82%). Established in 2001, IBB aims for high potential gains but carries higher regulatory risks due to its concentrated focus on biotech.
Investor Considerations
For investors, VHT is more suitable for conservative strategies focused on stability and dividend income. IBB may attract aggressive investors willing to accept higher volatility for the possibility of significant returns. While it includes established names in biotech, such as Amgen and Moderna, the high risk associated with smaller companies in its portfolio can lead to greater price fluctuations.
In summary, investors should weigh their risk tolerance and long-term goals when choosing between these two ETFs, as each presents distinct advantages and challenges. The deciding factors may include cost, diversification, and individual investment strategies.
The content above is a summary. For more details, see the source article.